Maojo et al Acknowledgments The work of the authors in this area of research has been partially funded by the European Commission (the ACTION-Grid Support Action, FP7-224176), and the INBIOMEDvision (Coordination and Support Action, FP7- 270107), the Spanish Ministry of Economy and Competi- tiveness (FIS/AES PS09/00069, RETICS COMBIOMED RD07/0067/0006, Ibero-NBIC CYTED 209RT0366), the Consejo Social of the Universidad Politécnica de Madrid, the Comunidad de Madrid and the National Center for Research Resources/National Center for Advancing Translational Sciences (Public Health Services research grants UL1-RR025764 and UL1RR025764-02S2). This project has also been funded in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. Disclosure Other than the funding outlined in the Acknowledgments, the authors declare no conflicts of interest in this work. References 1. Blum BI, Duncan K, eds. A History of Medical Informatics. New York, NY: ACM Press; Reading, MA: Addison-Wesley; 1990. 2. Ledley RS, Lusted LB. Reasoning foundations of medical diagnosis; symbolic logic, probability, and value theory aid our understanding of how physicians reason. Science. 1959;130(3366):9–21. 3. Kay L. Who Wrote the Book of Life? A History of the Genetic Code. Palo Alto, CA: Stanford University Press; 2000. 4. Collins FS, Morgan M, Patrinos A. The Human Genome Project: lessons from large-scale biology. Science. 2003;300(5617):286–290. 5. Gene Ontology Consortium. Creating the gene ontology resource: design and implementation. Genome Res. 2001;11(8):1425–1433. 6. Kulikowski CA. The micro-macro spectrum of medical informatics challenges: from molecular medicine to transforming health care in a globalizing society. Methods Inf Med. 2002;41(1):20–24. 7. Kohane IS. Bioinformatics and clinical informatics: the imperative to collaborate. J Am Med Inform Assoc. 2000;7(5):512–516. 8. Maojo V, Kulikowski CA. Bioinformatics and medical informatics: collaborations on the road to genomic medicine? J Am Med Inform Assoc. 2003;10(6):515–522. 9. Galperin MY, Fernández-Suárez XM. The 2012 Nucleic Acids Research Database Issue and the online Molecular Biology Database Collection. Nucleic Acids Res. 2012;40(Database issue):D1–D8. 10. Brooksbank C, Cameron G, Thornton J. The European Bioinformatics Institute’s data resources. Nucleic Acids Res. 2010;38(Database issue): D17–D25. 11. Wu C, Orozco C, Boyer J, et aI. BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol. 2009;10(11):R130. 12. Flicek P, Amode MR, Barrell D, et al. Ensembl 2012. Nucleic Acids Res. 2012;40(Database issue):D84–D90. 3882 submit your manuscript | www.dovepress.com Dovepress Dovepress 13. Maglott D, Ostell J, Pruitt KD, Tatusova T. Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res. 2011;39(Database issue): D52–D57. 14. Li Z, Liu X, Wen J, et al. DRUMS: a human disease related unique gene mutation search engine. Hum Mutat. 2011;32(10): E2259–E2265. 15. Schriml LM, Arze C, Nadendla S, et al. Disease Ontology: a backbone for disease semantic integration. Nucleic Acids Res. 2012;40(Database issue):D940–D946. 16. Jonquet C, Shah NH, Musen MA. The open biomedical annotator. Summit on Translat Bioinforma. 2009;2009:56–60. 17. Courtot M, Juty N, Knüpfer C, et al. Controlled vocabularies and semantics in systems biology. Mol Syst Biol. 2011;7:543. 18. Schofield PN, Hancock JM. Integration of global resources for human genetic variation and disease. Hum Mutat. 2012;33(5):813–816. 19. Kim BY, Rutka JT, Chan WC. Nanomedicine. N Engl J Med. 2010;363(25):2434–2443. 20. Freitas RA Jr. Nanomedicine, Volume I: Basic Capabilities. Georgetown, TX: Landes Bioscience; 1999.Available from: http://www.nanomedicine. com/NMI.htm. Accessed February 28, 2012. 21. Jain KK. A Handbook of Nanomedicine. Totowa, NJ: Humana/Springer; 2008. 22. Liu C, Zhang N. Nanoparticles in gene therapy principles, prospects, and challenges. Prog Mol Biol Transl Sci. 2011;104:509–562. 23. Bellare JR. Nanotechnology and nanomedicine for healthcare: challenges in translating innovations from bench to bedside. J Biomed Nanotechnol. 2011;7(1):36–37. 24. Maojo V, Martin-Sanchez F, Kulikowski C, Rodriguez-Paton A, Fritts M. Nanoinformatics and DNA-based computing: catalyzing nanomedicine. Pediatr Res. 2010;67(5):481–489. 25. Workshop on Nanoinformatics Strategies. 2007 June 12–13, Arlington, VA, USA. National Science Foundation – National Nanomanufacturing Network; nd. Available from: http://semanticommunity.info/@api/deki/ files/1347/=Purpose.pdf. Accessed February 28, 2012. 26. Lymberis A. Converging micro-nano-bio technologies towards integrated biomedical systems: state of the art and future perspectives under the EU-information and communication technologies program. Conf Proc IEEE Eng Med Biol Soc. 2008;2008:6–8. 27. Stone AJ, editor. The Theory of Intermolecular Forces. Oxford University Press; Oxford, England. 1996. 28. Zhou C, Yu J, Qin Y, Zheng J. Grain size effects in polycrystalline gold nanoparticles. Nanoscale. 2012. (Epub ahead of print). 29. Oezaslan M, Heggen M, Strasser P. Size-dependent morphology of dealloyed bimetallic catalysts: linking the nano to the macro scale. J Am Chem Soc. 2012;134(1):514–524. 30. Teli MK, Mutalik S, Rajanikant GK. Nanotechnology and nanomedicine: going small means aiming big. Curr Pharm Des. 2010; 16(16):1882–1892. 31. Ma X, Zhao Y, Liang XJ. Theranostic nanoparticles engineered for clinic and pharmaceutics. Acc Chem Res. 2011;44(10):1114–1122. 32. Youns M, Hoheisel JD, Efferth T. Therapeutic and diagnostic applications of nanoparticles. Curr Drug Targets. 2011;12(3):357–365. 33. Bharali DJ, Khalil M, Gurbuz M, Simone TM, Mousa SA. Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers. Int J Nanomedicine. 2009;4:1–7. 34. Harper S, Usenko C, Hutchison JE, Maddux BL, Tanguay RL. In vivo biodistribution and toxicity depends on nanomaterial composition, size, surface functionalisation and route of exposure. J Exp Nanosci. 2008;3(3):195–206. 35. Ruggiero C, Pastorino L, Herrera OL. Nanotechnology based targeted drug delivery. Conf Proc IEEE Eng Med Biol Soc. 2010;2010: 3731–3732. 36. Graham LM, Nguyen TM, Lee SB. Nanodetoxification: emerging role of nanomaterials in drug intoxication treatment. Nanomedicine (Lond). 2011;6(5):921–928. 37. Phan JH, Moffitt RA, Stokes TH, et al. Convergence of biomarkers, bioinformatics and nanotechnology for individualized cancer treatment. Trends Biotechnol. 2009;27(6):350–358. International Journal of Nanomedicine 2012:7